Tumor marker-based RecistTM is superior to RECIST as criteria to predict the long-term benefits of targeted therapy in advanced non-small-cell lung cancer with driver gene mutations
-
Published:2024-07
Issue:
Volume:53
Page:101006
-
ISSN:1476-5586
-
Container-title:Neoplasia
-
language:en
-
Short-container-title:Neoplasia
Author:
Xiong KaiORCID,
Yang Yi,
Yang Yanan,
Wang Zhengbo,
Liu Yun,
Duo Hong,
Yuan Xinya,
Xiao Yao,
Xiao He,
Yang XueqinORCID